- US-listed companies
- CymaBay Therapeutics, Inc.
- Income statement
CymaBay Therapeutics, Inc. (CBAY) Income statement
Market cap
$3.7B
P/E ratio
| 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
| Revenue | - | - | - | - | - | - | - | - | - | - | 31 |
| Research & development | 5 | 16 | 17 | 16 | 19 | 58 | 84 | 36 | 65 | 68 | 81 |
| Operating margin (%) | - | - | - | - | - | - | - | - | - | - | |
| Operating expenses | 9 | 24 | 26 | 26 | 31 | 73 | 108 | 53 | 88 | 93 | 133 |
| Operating income | -9 | -24 | -26 | -26 | -21 | -73 | -108 | -53 | -88 | -93 | -102 |
| Net income | -10 | -32 | -16 | -27 | -28 | -73 | -103 | -51 | -90 | -106 | -105 |
| Net income margin (%) | - | - | - | - | - | - | - | - | - | - | |
| Earnings per share | 103.52 | -2.65 | -0.82 | -1.14 | -0.79 | -1.25 | -1.53 | -0.74 | -1.27 | -1.21 | -0.99 |
| Diluted EPS | -3.54 | -2.65 | -0.83 | -1.14 | -0.79 | -1.26 | -1.53 | -0.74 | -1.27 | -1.21 | -0.99 |
| EBITDA | |||||||||||
| EBITDA margin (%) | - | - | - | - | - | - | - | - | - | - |